Please ensure Javascript is enabled for purposes of website accessibility

GW Pharmaceuticals' Marijuana-Based Drug Hits the Mark in Pivotal-Stage Study

By George Budwell – Mar 14, 2016 at 9:38AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The drugmaker's experimental therapy showed a significant reduction in symptoms for patients with a severe form of childhood epilepsy.

Image source: Pixabay.

What: Medical marijuana advocates are smiling today after GW Pharmaceuticals (GWPH) reported that its experimental treatment, Epidiolex, met its primary endpoint as a treatment for Dravet syndrome -- a severe form of epilepsy that presents in early childhood. The British drugmaker's shares jumped a whopping 130% in pre-market trading on heavy volume immediately after announcing the good news.

GW's management stated in its initial press release that Epidiolex led to a statistically significant reduction in convulsive seizures, compared with placebo (p=0.01), in its first pivotal late-stage study. 

So what: Epidiolex is a marijuana-based medicine (cannabidiol). While such drugs have certainly grabbed headlines in the U.S. because they are believed to be "natural" and perhaps less costly to develop than synthetic compounds, the clinical data so far has painted a mixed picture in terms of their effectiveness. In brief, this pivotal-stage study is among the first to provide compelling evidence that marijuana-based medicines may indeed have an important role to play when it comes to treating devastating diseases such as Dravet syndrome, and perhaps many others. 

Now what: GW Pharmaceuticals now plans on meeting with the FDA to discuss a potential regulatory filing for Epidiolex based on these positive late-stage data. In the interim, the company is waiting on the drug's other late-stage trials -- one for Lennox-Gastaut syndrome and another for Dravet syndrome -- to wrap up. 

While these pivotal-stage data are promising, investors need to understand that these results don't necessarily guarantee a regulatory approval in the U.S. After all, the FDA has little experience with marijuana-based medicines, making it particularly difficult to predict the types of regulatory pitfalls that may lie ahead for Epidiolex. 

George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

GW Pharmaceuticals Stock Quote
GW Pharmaceuticals

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.